aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 5.84 USD -11.65% Market Closed
Market Cap: 519.8m USD

Net Margin
aTyr Pharma Inc

0%
Current
-6 877%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-63.4m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
aTyr Pharma Inc
NASDAQ:ATYR
519.8m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.1B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
165.2B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
145.3B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
130.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.3B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

aTyr Pharma Inc
Glance View

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.

ATYR Intrinsic Value
7.39 USD
Undervaluation 21%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-63.4m
/
Revenue
0
What is the Net Margin of aTyr Pharma Inc?

Based on aTyr Pharma Inc's most recent financial statements, the company has Net Margin of 0%.

Back to Top